Cisplatin resistance-related transcriptome and methylome . . . - Cell Press To identify cisplatin resistance-associated genes that may be regulated by DNA methylation, we first collected gene expression data and cisplatin IC50 values in 54 SCLC cell lines from GDSC SCLC cell lines were divided into 13 cisplatin-sensitive cell lines (IC50 < 10) and 41 cisplatin-resistant cell lines (IC50 > 10) ( Figure 2 A; Table S1 )
Drug: Cisplatin - Cancerrxgene - Genomics of Drug Sensitivity in Cancer The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA) This work is funded by Wellcome
Proteome analysis of non-small cell lung cancer cell line secretomes . . . Spearman correlation analysis correlating protein expression with IC50 values for cisplatin across all 6 NSCLC cell lines (Corr analysis) and 2-group comparison (beta-binomial test; 2-gr analysis) of protein expression between the 2 cell lines with lowest and the 2 cell lines with highest cisplatin sensitivity identified proteins with
Generation and Characterisation of Cisplatin-Resistant Non-Small Cell . . . Introduction Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management of non-small cell lung cancer (NSCLC) Understanding the molecular mechanisms underlying this process may result in the development of novel agents to enhance the sensitivity of cisplatin Methods An isogenic model of cisplatin resistance was generated in a panel of NSCLC cell
Cisplatin resistance-related multi-omics differences and the . . . Platinum-based chemotherapies are currently the first-line treatment of non-small cell lung cancer This study will improve our understanding of the causes of resistance to cisplatin, especially in lung adenocarcinoma (LUAD) and provide a reference for therapeutic decisions in clinical practice Cancer Cell Line Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA) and Zhongshan hospital
Resistance mechanism to cisplatin in NCI-H460 non-small cell lung . . . Aim: To investigate the effects of cisplatin on the human non-small cell lung carcinoma (NCI-H460) cell line regarding cytotoxicity, genotoxicity, and expression of genes associated with apoptosis (BIRC5) and autophagy (BECN1) Methods: Cell cultures were treated with cisplatin concentrations (0 16-33 3 μmol L) for 48 h Mutagenicity and acute and chronic cytotoxicities were assessed using the
Disparities in Cisplatin-Induced Cytotoxicity—A Meta-Analysis of . . . Cisplatin is a classic anticancer drug widely used as a reference drug to test new metal complex drug candidates We found an unexpected diversity in cisplatin-related cytotoxicity values, expressed as IC50 (the half-maximal inhibitory concentration) in tumour cell lines, such as MCF-7, HepG2 and HeLa We reviewed the data published from 2018 to 2022 A total of 41 articles based on 56 in
GLIDR-mediated regulation of tumor malignancy and cisplatin resistance . . . Lung cancer is the second most diagnosed cancer worldwide, causing more than 1 5 million deaths annually [] Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases [] Unfortunately, the five-year overall survival of NSCLC patients is less than 15%, primarily due to late-stage diagnosis, limited therapeutic options, and the acquisition of treatment resistance [3, 4]
A bioinformatics-based study on the Cisplatin-resistant lung cancer . . . To evaluate whether Cisplatin resistance is induced in A549 cells, we used the MTT assay, and the results illustrated that Cisplatin IC50 in the resistant A549 cell line is approximately 6 53 µg ml (Fig 4 A) Surprisingly, sensitive A549 cells showed the Cisplatin IC50 = 0 5585 µg ml (Fig 4 B)
Cytotoxicity analysis of etoposide and cisplatin on cell lines from . . . Keywords: Cytotoxicity, cell culture, lung cancer, cell lines, etoposide, cisplatin *Corresponding author E-mail: gwomforreal2015@gmail com INTRODUCTION Lung cancer is one of the most commonly occurring and deadliest human cancers worldwide (Pervaiz et al , 2010); with an annual incidence of 1 8 million (Yousheng et al 2016)
Cisplatin-resistance and aggressiveness are enhanced by a highly stable . . . Lung cancer is currently the leading cause of death by cancer worldwide [], rendering this disease a major public health problem Over 80% of incidence corresponds to non-small cell lung cancer (NSCLC), and the main first-line treatment for advanced stages is cisplatin chemotherapy [2, 3] Despite this, a considerably high recurrence rate occurs following cisplatin treatment and a poor 5-year
Lung cancer cells and their sensitivity resistance to cisplatin . . . Lung cancer is the most prevalent cancer all over the world, responsible for the highest number of deaths compared to other types of cancer [1] Among two sorts of lung cancer including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), NSCLC has the highest incidence rate and patients with this type of lung cancer suffer from poor prognosis and low 5-year survival rate [2, 3]